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The Annual bioProcessUK Conference has acted as the key
networking event for bioprocess scientists and engineers in
the UK for the past 10 years. The following article is a report
from the sessions that focused on continuous bioprocessing
during the 10th Annual bioProcessUK Conference (London,
December 2013). These sessions were organized by the
‘EPSRC Centre for Innovative Manufacturing in Emergent
Macromolecular Therapies’ hosted at University College
London. A plenary lecture and workshop provided a forum
for participants to debate topical issues in roundtable
discussions with industry and academic experts from
institutions such as Genzyme, Janssen, Novo Nordisk, Pﬁzer,
Merck, GE Healthcare and University College London. The aim
of these particular sessions was to understand better the
challenges and opportunities for continuous bioprocessing in
the bioprocessing sector.
Introduction
The 10th Annual bioProcessUK conference was held in Lon-
don on 3–4 December 2013, with the theme ‘Biopharmaceutical
Innovation: a Vision for the Future’. The EPSRC Centre for
Innovative Manufacturing in Emergent Macromolecular Thera-
pies was host sponsor for the conference. The Centre was invited
by the conference organizer, bioProcessUK, to arrange and chair
a plenary session, as well as a workshop on the “Operational and
Economic Challenges of Continuous Bioprocessing” in response
to the resurgent interest in this topic. Companies are now asking
whether they should choose conventional batch technologies or
invest in novel continuous technologies, which may lead to lower
production costs. This has led to several companies evaluating
continuous technologies [e.g. ref. 1–4] to see if they can leverage
their benefits, which include potentially allowing smaller facility
footprints and higher equipment utilization rates. This report
summarizes the presentations and discussion arising from these
sessions.
Plenary Session
Konstantin Konstantinov from Genzyme-Sanofi presented a
plenary lecture with an industrial perspective on advancing the
case for integrated continuous bioprocesses.1,2,5 Dr Konstantinov
opened by highlighting the lengthy but highly successful evolu-
tionary path of continuous manufacturing in other industries
such as steel casting, which enabled these businesses to operate at
a different level of industrialization. He highlighted that investi-
gations into continuous manufacture for biologics are being
encouraged by the recent US Food and Drug Administration’s
strategic plans6 and Quality by Design (QbD) initiatives. He pre-
sented Genzyme’s successful implementation of an integrated,
closed and fully continuous biologics processing platform. Recent
results were shown for the production of both stable (monoclonal
antibody) and less stable (enzyme) proteins in an uninterrupted
manner over extended periods with consistent time-based system
performance and product quality. The platform demonstrated
the integration of a perfusion bioreactor with 2 continuous chro-
matography steps for capture and polishing of protein therapeu-
tics. Dr Konstantinov presented a vision for a future universal
platform for the production of protein therapeutics that relied on
continuous processing with a dramatic reduction in the facility
footprint, elimination of non-value-added steps and reduction in
the number of unit operations to a minimum. Such examples are
important demonstrations of proof-of-concept for the sector and of
the transformative potential of integrated continuous bioprocesses.
Workshop
The aim of the workshop was to address the drivers, costs,
risks and benefits that influence the implementation of continu-
ous bioprocessing. Suzanne Farid (University College London)
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chaired the workshop and introduced the discussion topics that
were prioritized under the following 4 core themes:
Theme 1: Fed-batch versus perfusion culture for stable products?
Theme 2: Is there a business case for continuous chromatography
linked to fed-batch or perfusion culture?
Theme 3: How do you balance COG savings with continuous
bioprocesses with cost of development and flexibility?
Theme 4: Is tomorrow’s process a hybrid of batch and continuous
operations?
Each theme was introduced with an industrial perspective to
kick-start the roundtable discussions. Over 80 industrial and aca-
demic participants attended the workshop. The topic of this work-
shop was similar to one co-chaired by Dr Farid at the Engineering
Conferences International’s Integrated Continuous Bioprocessing
Conference held in Barcelona, Spain in October 2013.
Theme 1: Fed-batch vs. perfusion culture for stable products
Patrick Sheehy from Janssen Biologics (formerly Centocor)
shared insights from his experience with both perfusion and fed-
batch culture up to 1000 L scale for both clinical trial and in-
market supply. The company’s early commercial antibodies, such
as abciximab (Reopro) and infliximab (Remicade), were origi-
nally based on perfusion culture using internal and external spin-
filters to retain the cells.7 Now extensive use is made of more
recent retention devices such as the external alternating tangential
flow (ATF) filtration systems in conjunction with perfusion for
products such as golimumab (Simponi) and ustekinumab
(Stelara).8 Practical challenges encountered with perfusion pro-
cesses developed in the late 1990s and early 2000s relate to equip-
ment fouling, high costs for proprietary media and the expertise
required for these more complex processes. Equipment failures
were seen with early perfusion processes due to fouling of internal
spin filters that led to termination of the cultures. Although all
retention devices foul during perfusion cultures, the rate of foul-
ing seen with ATF filters was lower and not considered a major
concern given the capability to replace the filters out without too
much disruption to the perfusion culture.
Although perfusion processes continue to be used for mar-
keted antibody products, Janssen has moved to fed-batch process-
ing for future stable antibody products going into clinical trials.
From Janssen’s perspective, fed-batch offers lower complexity
and lower risk of failure, as well has higher titers. Lower complex-
ity means processes are easier to operate and product changeovers
are simpler, an important consideration for multi-product facili-
ties. Janssen’s choice is also influenced by the fact that its devel-
opment products are quite stable antibodies, and these can be
more suited to fed-batch processing than more labile products.
Looking forward, Dr Sheehy noted that the choice of process
route would be kept under review. New perfusion processes are
very different from those originally developed 10 years ago.
Higher cell densities and productivities are achievable and better
bioreactor control is available. The potential use of disposables
helps make continuous processing a lower capital cost choice for
the upstream operations, although there are scale limitations.
Theme 2: Is there a business case for continuous
chromatography linked to fed-batch or perfusion culture?
James Pollock from Merck shared cost of goods (COG)
insights from his doctorate research on evaluating the potential
of continuous processes at different stages of the development
lifecycle, carried out in the Decisional Tools team at University
College London Biochemical Engineering led by Dr Suzanne
Farid and in collaboration with Pfizer. He addressed the follow-
ing topical questions:
 How well do continuous bioprocess steps need to perform to
compete with the traditional batch steps?
 Is there a business case for continuous bioprocessing for early
phase manufacture?
 How does the business case change for commercial multi-
product manufacture?
He presented 3 industrial case studies9-11 that provided eco-
nomic and operational perspectives on the decision to select
batch versus continuous processes for upstream, downstream and
integrated continuous processes. On the upstream front, Dr Pol-
lock illustrated how the choice of fed-batch vs. spin-filter and
ATF perfusion culture depends on the scale of production, failure
rate and cell density increase achievable. ATF perfusion processes
were predicted to be more competitive for single-product com-
mercial facilities if the cell density increase was above a critical
threshold (3-fold higher than fed-batch in this commercial anti-
body production case) and the process economics savings were
considered more important than operational feasibility. The sav-
ings with ATF perfusion processes were due to the smaller foot-
print upstream and downstream suites enabled by their higher
cell densities and volumetric productivities, the ability to use sin-
gle-use bioreactors and to replace a fouled retention device dur-
ing a culture. In contrast, spin-filters generally did not match the
cost or robustness benefits of either fed-batch or ATF processes.
Several of the major biopharmaceutical companies are assess-
ing continuous chromatography from suppliers such as GE, Tar-
pon and Novasep. Such systems are in reality semi-continuous,
utilizing 3–12 columns in a periodic counter-current configura-
tion. Dr Pollock showed that continuous capture chromatogra-
phy enabled more efficient utilization of Protein A which is
particularly significant for early phase manufacture where materi-
als represent a greater proportion of the COG. This can have a
large effect on clinical manufacturing costs considering the high
clinical attrition rates. Extending this to integrated continuous
bioprocesses for multi-product clinical and commercial manufac-
ture, the analysis predicts that an integrated continuous strategy
(ATF perfusion, continuous capture, continuous polishing) is
cost-effective for early phase production and small/medium-sized
companies. However, the ranking of strategies switches for com-
mercial production and large companies to the hybrid strategy
with fed-batch culture, continuous capture and batch polishing
since this avoids the need for multiple parallel trains with the
scale-limited perfusion systems.
The insights from the analysis act as a valuable test bed for assessing
the potential of novel continuous strategies to cope with different
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scales of operation, phases of development and company sizes. The
analysis demonstrated that continuous processing can offer COG
benefits in different scenarios. Further considerations outside the
scope of this work include the impact of adopting continuous process-
ing on process development efforts. This was discussed in Theme 3.
Theme 3: How do you balance COG savings with cost of
development and flexibility?
Haleh Ahmadian from Novo Nordisk considered the balance
between cost, quality and time when introducing continuous bio-
processing. She first addressed the dilemma of cost for biophar-
maceutical manufacture. On the one hand, COG is a minor
percentage of the high prices of biopharmaceuticals. For instance,
drug substance COG values for monoclonal antibodies are
reported to be around 100 USD per gram, while the sales price
of final product varies in the range of 2,000–20,000 USD per
gram.12 There is thus little financial incentive to spend money to
bring COG down while ensuring positive return on investments.
On the other hand, the pressure from capacity constraints, biosi-
milars and price differentiation for some products are in favor of
reducing COG. She commented that, although price pressures
from biosimilars may be considered by some not to be compel-
ling, it is expected that this will change as the sector matures.
Examples of efforts to enable price differentiation included post-
approval changes to optimizing manufacturing for insulin and
growth hormone products so as to reduce their COG.
She presented a managerial view to address the question of
how to reduce timelines and COG without compromising qual-
ity. From an organizational perspective, her view of the solution
is to build up an organization that will support this with strategic
alignment, standardization, platforms and most importantly,
early technology development to make sure that new technology
does not delay time to market.
Dr Ahmadian presented Novo Nordisk’s 2-stage process devel-
opment model where the first stage focused on development of an
initial process to cover early phase material with limited experimen-
tation and the second stage on design to manufacture for process
robustness. However, for new technologies such as continuous bio-
processing, this model does not work and technology development
needs to start early to remain off the critical path.
Dr Ahmadian then brought the time to develop new processes
into the equation considering both risk and quality. New technolo-
gies that offer favorable COG values still pose a risk since they may
not be very well characterized and may incur extra process develop-
ment costs to develop a process that delivers a high quality product.
She stressed that the balance between COG savings and the cost of
process development would need to be assessed on a case-by-case
basis and would be product-dependent (e.g., different solutions for
coagulation factors versus insulin) and be affected by whether the
product was registered in the Center for Drug Evaluation and
Research or the Center for Biologics Evaluation and Research in the
US Food andDrug Administration.
Novo Nordisk has experienced situations where continuous
bioprocessing was proposed but the cost of development could
not be justified, and, conversely, a case where continuous biopro-
cessing turned out to be the most feasible and practical option.
Theme 4: Is tomorrow’s process a hybrid of batch and
continuous operations?
Karol Lacki from GE opened by drawing parallels with the
industry’s response to “lean” manufacturing a few years ago and
“continuous” manufacturing now. Both encourage the removal
of non-value added steps such as intermediate filtration and wash
operations so as to lead to leaner processes that translate into
time and cost savings. Dr Lacki presented a helicopter view of
hybrid options, including current commercial hybrid processes
using perfusion culture and standard batch processes for purifica-
tion. He then addressed the question of whether downstream
processing can be operated in a continuous mode. He outlined
the different continuous chromatography technologies currently
available for capture chromatography from vendors that each aim
to improve the utilization of the resin capacity. These include the
periodic counter current (PCC) system (3–4 columns) from GE
Healthcare (Uppsala, Sweden), BioSC (2–6 columns) from
Novasep (Pompey, France), BioSMB (6–12 columns) from Tar-
pon (Leiden, Netherlands) and SMBC (4–8 columns) from
Semba Biosciences (Madison, WI).
Dr Lacki then discussed challenges connecting continuous
capture and polishing steps. He highlighted efforts reported in
conferences from Genzyme, GE Healthcare/Janssen, Amgen and
Sanofi that have led to a number of quasi-continuous purification
trains. The trains comprise chromatography steps connected in
series with no break-up times or hold-up times. These efforts
have focused on in-line adjustment of process streams between
columns to enabling continuous flow operation (e.g., GE/
Janssen’s “straight through processing”13 or careful selection of
buffers to avoid the need for pH/conductivity adjustment
between steps (e.g., Sanofi’s ASAP system14).
Dr Lacki felt that both hybrid and continuous manufacturing
scenarios will co-exist in future. Yet, certain conditions must be
met. The clear advantage of continuous capture steps where the
consumption of expensive resin is reduced is less evident for pol-
ishing steps which may operate discontinuously. Despite a few
successful examples of continuous or semi-continuous chroma-
tography operations, certain purification steps such as virus inac-
tivation with its incubation time can turn a continuous
purification train into a hybrid one. Although there have been
efforts to operate virus inactivation in a continuous mode such as
Merck’s tubular reactor design,15 Dr Lacki presented the
dilemma of whether the industry should consider removal of
steps where continuous solutions do not exist or identify ways to
work around them.
The View from the Audience
The roundtable discussions led to a lively discussion that
tapped into the experiences of the audience, which were primarily
with batch rather than continuous processes. However, a quick
survey of the audience revealed that over half were considering
evaluating continuous processes for both upstream and down-
stream in the near future. Some already had begun the evalua-
tion, but had not yet implemented it in manufacturing.
www.landesbioscience.com 1359mAbs
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 06
:58
 24
 M
arc
h 2
01
5 
On Theme 1, the roundtable discussions revolved around
challenges when dealing with the extra complexity posed by
continuous culture. The viewpoints on complexity varied
based on the exposure of the delegates to continuous biopro-
cessing. Delegates from small companies noted that, although
in the models there were cost advantages for using perfusion
systems, there were also some challenges. The difficulty in
process definition at a small scale and disadvantage of poten-
tially having to change to fed-batch processing later repre-
sented increased risk and uncertainty. The robustness of
equipment over long runs was also raised as a concern, as
was the ability to define and trace batches unambiguously.
For some small companies, speed into clinical trials was more
important than the cost of goods and using simpler and
more familiar processes with reliable scale-down tools for
development offered a faster and lower risk option. Compa-
nies with experience running continuous culture for stable
antibody products and labile products, such as enzymes and
blood factors, commented that the batch definition challenges
have been addressed and that the number of process devia-
tions are comparable to fed-batch processes. They recognized
that addition of retention devices adds complexity, but that
the evolution of retention devices with lower failure rates and
faster time to recover has increased the robustness of perfu-
sion culture runs.
On Theme 2, the discussions focused on the business case for
continuous processes and the benefits needed to balance the per-
ceived risk in switching to continuous. Representatives from
larger companies were careful to balance the potential cost sav-
ings of continuous upstream processing against the increased pro-
cess complexity and uncertainty. For one contributor,
performance in terms of production quantity per reactor per unit
time would have to double and the cost would have to halve to
balance the increase risk and uncertainty. Without the prospect
of such a large benefit, it would not be possible to justify the risk
in exploring the continuous option. The market size of a develop-
ment product may not be clear until after the early phase clinical
trials, and in this situation a fed-batch process may allow the crit-
ical decision point to be reached more quickly and enable a fast-
to-failure strategy across a development portfolio. When the mar-
ket requirements are clear, and there is a good commercial case,
continuous upstream processing can be made to work.
The potential payback is very much influenced by whether the
proposed plant is a greenfield plant or a retrofit of an existing
plant. The balance of risks and benefits can also be significantly
different for more labile products where continuous processing
offers some real advantages. The lack of reliable scale-down tools
for continuous processes was mentioned by a number of the audi-
ence as an additional challenge.
On Theme 3, the development effort required for continuous
bioprocesses was debated. The majority of the delegates consid-
ered that the consequences on the cost and time of development
would take priority over COG savings when considering the
implementation of continuous bioprocessing. There were some
exceptions (e.g., for biosimilars) where COG savings can be
more critical to competitiveness in the market. New technologies
also pose risk due to uncertainty about their performance, but
can ultimately lead to processes that are more robust. The audi-
ence debated whether continuous processes had the potential to
offer increased robustness, and whether that would also outweigh
COG.
Roundtable discussions on validation highlighted that there
were differing views, with some people believing continuous pro-
cesses could streamline validation efforts, while others believe it
is more complex to validate and could lengthen development
times. This will depend on the product and when the develop-
ment starts. The argument for streamlining development and val-
idation efforts relies on the fact that there would be no need to
scale-up the process as it moved through the development cycle
and higher demands would be met by addition of parallel pro-
duction lines. For companies with in-house expertise, running
continuous perfusion culture for commercial processes the transi-
tion to integrated continuous bioprocesses could save develop-
ment times. On the continuous chromatography front,
validation challenges relate to control software and equipment
performance qualification.
There are also differing views about quality obtained from
continuous processes. Genzyme and others (see for example ref.
16,17) have reported that steady-state operation for antibody
production gives less heterogeneity in glycosylation profiling
than fed-batch cultures. The heterogeneity in antibodies in fed-
batch might have clinical significance; this is not known, but
remains a big question mark.
On Theme 4, the discussions focused on whether
tomorrow’s process would be a hybrid of batch and continu-
ous operations and the gaps that exist to create an integrated
continuous bioprocess. Several attendees felt that a continu-
ous bioprocess will rely on smaller equipment that is operated
more frequently with a higher level of automation. The audi-
ence recognized that a major challenge affecting the uptake
of continuous bioprocessing relates to the availability of
robust online analytics and control strategies. They consid-
ered that the necessary process analytics to run continuous
processes should be available in a 5 year time frame. The
ability of tomorrow’s processes to adapt easily to different
manufacturing scenarios, including both batch and continu-
ous operations, without changes in basic downstream technol-
ogies was also considered important as the sector advances.
The Final Word
In summary, the final views from the audience on issues to
consider when evaluating a transition toward integrated continu-
ous bioprocesses were:
1. Media development will become important for optimizing
the costs and logistics in perfusion systems;
2. Continuous bioprocessing (particularly in downstream) needs
better online process analytics (PAT), control and hardware
reliability than is currently available, but in 5 years’ time that
issue may be resolved;
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3. Development cost is a more important consideration than
manufacturing cost (at least in the early stages), and until that
changes, significant investment in COG reduction alone will
be difficult to justify;
4. Single-use technologies could reduce COG as much as con-
tinuous processing;
5. The complexity of continuous bioprocesses may be mitigated
by using single-use or disposable technologies and this combi-
nation could accelerate industry uptake;
6. The choice between batch and continuous operations will
depend on the long-term objectives of the facility (e.g., clini-
cal vs. commercial manufacture), the level of in-house exper-
tise with the technologies, the level of support from the
organization and its strategic and operational philosophy.
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